Viewing Study NCT01873833


Ignite Creation Date: 2025-12-25 @ 2:51 AM
Ignite Modification Date: 2026-03-05 @ 4:33 AM
Study NCT ID: NCT01873833
Status: TERMINATED
Last Update Posted: 2023-10-05
First Post: 2013-06-06
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Sponsor: University of Southern California
Organization:

Organization Data

Organization:
Class: OTHER
Study ID: 1B-12-10
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators

Collaborators

Name Class View
None NIH View